This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Are Two Antidepressant Mechanisms Better Than One? Issues in Clinical Trial Design and Analysis

Andrew C. Leon, PhD

Published: March 1, 2004

Article Abstract

The introduction of newer antidepressants that affect both serotonergic and noradrenergic neurotransmissionhas prompted the question of whether two antidepressant mechanisms of action are betterthan one for the treatment of depression. Existing data do not provide a definitive answer. Whetherfuture studies provide the answer will depend largely on the quality of trial designs. Some design aspectsare dictated by the nature of such a study (e.g., superiority vs. equivalence trial), and others aresomewhat more discretionary (e.g., assessment tools, statistical procedures). Issues in the design andanalysis of clinical trials comparing dual- and single-action antidepressants are discussed.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...